<DOC>
	<DOCNO>NCT01403181</DOCNO>
	<brief_summary>Analysis HCV-specific T cell responses patient treat boceprevir ass whether therapy induce restoration T cell function extent recovery achieve</brief_summary>
	<brief_title>Effect Boceprevir HCV-specific T Cell Responses</brief_title>
	<detailed_description>Reconstitution antiviral T cell function may represent component anti-viral effect protease inhibitor . If T cell responsiveness restore therapy , potentiation anti-viral T cell function exogenous T cell stimulation might exploit complement improve response available therapy . Monitoring T cell function might also useful predict accurately response therapy . To address issue , phenotype function HCV-specific T cell analyze longitudinally , therapy naïve genotype 1 chronic hepatitis C patient treat peginterferon plus ribavirin peginterferon ribavirin plus boceprevir . To analyze global CD4 CD8 reactivity structural non-structural HCV protein wide panel peptide correspond whole HCV genome genotype 1 employ . To analyze CD8 reactivity , HLA-A2/peptide tetramers use HLA-A2 positive patient directly quantify ex vivo HCV-specific CD8 cell circulate peripheral blood.The T cell function analyze capacity expansion vitro , cytokine production cytotoxicity .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible participation study . Male female , age 18 70 year old , inclusive . Willing able provide write informed consent Chronic HCV infection least 6 month prior baseline ( Day 1 ) subject currently positive HCVRNA antiHCV antibody document : A positive antiHCV antibody test , positive HCVRNA assay , HCV genotype test least 6 month prior baseline ( Day 1 ) A liver biopsy perform prior baseline ( Day 1 ) evidence chronic HCV infection Subjects must liver biopsy result ( perform two year prior screen ) indicate absence cirrhosis HCV infection limit genotype 1 Detectable plasma HCVRNA screen BMI 18 36 Kg/m2 Eligible subject must also HCV treatmentnaïve , define prior exposure PEGINF ribavirin , must eligible standard care therapy PEG/RBV Subjects must follow laboratory parameter screen : ALT AST ≤ 5 x upper limit normal range ( ULN ) Hemoglobin ( Hb ) ≥ 12 g/dl WBC ≥ 2.500 cells/μL absolute neutrophil count ≥ 1500 cells/μL If woman childbearing potential , must negative serum βhuman chorionic gonadotropin ( βHCG ) pregnancy test document screen visit negative serum urine pregnancy test first dose study drug ensure pregnant time start treatment A female subject childbearing potential nonvasectomized male subject female partner childbearing potential must agree partner use effective contraception ( two separate form contraception simultaneously , one must male condom spermicide ) screen throughout duration study treatment least 7 month Pregnant woman woman may wish become pregnant course study Male female pregnant planning become pregnant within seven month study anticipate last dose ribavirin Evidence infection coinfection nogenotype 1 HCVstrain History hemoglobinopathy History sarcoidosis History invasive malignancy diagnose treat within 5 year . Untreated significant psychiatric illness include severe depression , schizophrenia , psychosis , history suicide attempt Coinfection HBV HIV Chronic use systemic immunosuppressive agent Presence autoimmune disorder ; subject treat hypothyroidism normal TSH may enrol History significant cardiac disease Clinical evidence chronic pulmonary disease Known cirrhosis History solid organ transplantation Suspicion hepatocellular carcinoma Chronic liver disease nonHCV etiology Ongoing alcohol abuse History clinical relevant drug abuse Positive urine screen cocaine , opiate etc , methadone use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HCV</keyword>
	<keyword>T cell</keyword>
	<keyword>cytokine</keyword>
	<keyword>cytotoxicity</keyword>
	<keyword>proliferation</keyword>
</DOC>